Product Description
Shanghai Miracogen is developing MRG-004A as a treatment for advanced or metastatic solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04843709)
Mechanisms of Action: TFP Blocker
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Miracogen
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07138846 |
MRG004A-002 | P3 |
Not yet recruiting |
Pancreatic Cancer |
2027-06-01 |
20% |
2025-08-26 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/21/2025 |
News Article |
Lepu Biopharma (2157.HK) announces 2025 interim results |
|
06/12/2024 |
News Article |
2024ASCOļ½Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations |
|
05/30/2024 |
News Article |
OneOncology Highlights Research Contributions at 2024 ASCO Annual Meeting |
|
07/01/2023 |
PubMed |
Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function. |
|
03/15/2023 |
PubMed |
Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology. |
|
09/29/2021 |
News Article |
Third ADC with Synaffix's Technology Enters Clinical Development |